Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases

Basit Öğe Kaydı
dc.contributor.authorYilmaz N.
dc.contributor.authorEmmungil H.
dc.contributor.authorGucenmez S.
dc.contributor.authorOzen G.
dc.contributor.authorYildiz F.
dc.contributor.authorBalkarli A.
dc.contributor.authorKimyon G.
dc.contributor.authorCoskun B.N.
dc.contributor.authorDogan I.
dc.contributor.authorPamuk O.N.
dc.contributor.authorYasar S.
dc.contributor.authorCetin G.Y.
dc.contributor.authorYazici A.
dc.contributor.authorEsmen S.E.
dc.contributor.authorCagatay Y.
dc.contributor.authorYilmaz S.
dc.contributor.authorCefle A.
dc.contributor.authorSayarlioglu M.
dc.contributor.authorKasifoglu T.
dc.contributor.authorKaradag O.
dc.contributor.authorPehlivan Y.
dc.contributor.authorDalkilic E.
dc.contributor.authorKisacik B.
dc.contributor.authorCobankara V.
dc.contributor.authorErken E.
dc.contributor.authorDireskeneli H.
dc.contributor.authorAksu K.
dc.contributor.authorYavuz S.
dc.date.accessioned2019-10-26T21:27:06Z
dc.date.available2019-10-26T21:27:06Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective. To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases. Methods. Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics. Results. We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4-48) and bladder cancer was 8 years (6-10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p = 0.08]. Cumulative CYC dose (HR for 10-g increments 1.24, p < 0.001) was associated with hemorrhagic cystitis. Conclusion. Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort. © 2015 All rights reserved.en_US
dc.identifier.doi10.3899/jrheum.150065en_US
dc.identifier.endpage1666en_US
dc.identifier.issn0315-162X
dc.identifier.issue9en_US
dc.identifier.pmid26178288en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1661en_US
dc.identifier.urihttps://doi.org/10.3899/jrheum.150065
dc.identifier.urihttps://hdl.handle.net/11454/17393
dc.identifier.volume42en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJournal of Rheumatologyen_US
dc.relation.ispartofJournal of Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHemorrhagic cystitisen_US
dc.subjectMesnaen_US
dc.subjectRheumatic diseasesen_US
dc.titleIncidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseasesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu